Officially, the FDA cites: Insufficient large-scale clinical trials Concerns about consistency, sourcing, and manufacturing standards The need to meet formal drug approval requirements Critics argue (fairly) that this system: Favors large pharmaceutical companies Makes it hard to approve naturally occurring peptides Leaves promising, low-risk compounds in regulatory limbo The short version: This FDA restrictive regulatory change of mind wasnt driven by a sudden safety scare, it was driven by regulatory process and economics
-carotene suppresses osteoclastogenesis and bone resorption by suppressing NF-B signaling pathway
Nerelius C, Sandegren A, Sargsyan H, Raunak R, Leijonmarck H, Chatterjee U, Fisahn A, Imarisio S, Lomas DA, Crowther DC, Strmberg R (2009) -helix targeting reduces amyloid- peptide toxicity
Before making treatment recommendations, providers review: This evaluation helps ensure that treatment decisions are individualized and medically appropriate